Osijek Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
Department of Oncology, Osijek University Hospital Center, Osijek, Croatia.
Acta Clin Croat. 2022 Aug;61(2):239-247. doi: 10.20471/acc.2022.61.02.10.
The aim was to identify immunohistochemical (IHC) markers able to predict recurrence of urinary bladder tumors. The method of multivariate adaptive regression splines (MARS) was applied to IHC data of 33 patients with urinary bladder cancer that relapsed one to six times (24 male and nine female, age 57-87 years). The MARS analysis was used to predict the total number of recurrences and the Ki-67 value by nine IHC markers (epidermal growth factor receptor (EGFR), HER2, HER3, E-cadherin, Ki-67, MLH1, MSH2, MSH6 and PMS2). Data were divided as initial tumors, first and subsequent recurrences, and tumors that relapsed within nine months of previous surgery or later. The IHC markers were semiquantitatively classified into four groups, as follows: 0 means no positive cells; 1, 10% of positive cells; 2, 11%-30% of positive cells; and 3, 31%-100% of positive cells. In predicting the overall number of recurrences, as a surrogate marker of tumor biology, the R value for all tumors was 0.423, for initial tumors 0.686, for first recurrence 0.700, and for subsequent recurrences only 0.233. The key predictors for initial tumors were HER2 and MSH2, while for the first recurrence it was EGFR. For quick recurrences (within nine months), the R was 0.474 with EGFR and HER3 as predictors, while for slow recurrences R was 0.640 due to EGFR and PMS2. In predicting the Ki-67 value of that tumor, the R value for all tumors was 0.300, for initial tumors 0.262, for first recurrence 0.360, and for subsequent recurrences only 0.533. The key predictors for first recurrences were EGFR and MSH6, and for subsequent recurrences HER2, EGFR and all Lynch markers. The R was 0.266 for quick recurrences and 0.370 for slow recurrences. The finding of E-cadherin was not found relevant by any of these MARS models. In conclusion, the MARS results associated multiple IHC markers with the number of recurrences and with Ki-67 values. It is important that differences in predictive markers were found between initial tumors and first recurrences, and between quick and slow recurrences, thus suggesting that tumor biology is different among these subgroups regarding the total number of recurrences and Ki-67 values.
目的是确定能够预测膀胱癌复发的免疫组织化学(IHC)标志物。应用多变量自适应回归样条(MARS)方法对 33 例膀胱癌患者的 IHC 数据进行分析,这些患者的膀胱癌复发 1-6 次(24 例男性,9 例女性,年龄 57-87 岁)。MARS 分析用于通过 9 种 IHC 标志物(表皮生长因子受体(EGFR)、HER2、HER3、E-钙粘蛋白、Ki-67、MLH1、MSH2、MSH6 和 PMS2)预测总复发次数和 Ki-67 值。数据分为初始肿瘤、首次复发和随后复发,以及手术后 9 个月内或以后复发的肿瘤。IHC 标志物被半定量地分为四组,如下所示:0 表示无阳性细胞;1 表示 10%的阳性细胞;2 表示 11%-30%的阳性细胞;3 表示 31%-100%的阳性细胞。在预测总复发次数方面,作为肿瘤生物学的替代标志物,所有肿瘤的 R 值为 0.423,初始肿瘤为 0.686,首次复发为 0.700,随后复发仅为 0.233。初始肿瘤的关键预测因子是 HER2 和 MSH2,而首次复发的关键预测因子是 EGFR。对于快速复发(9 个月内),R 值为 0.474,预测因子为 EGFR 和 HER3,而对于缓慢复发,R 值为 0.640,预测因子为 EGFR 和 PMS2。在预测肿瘤 Ki-67 值方面,所有肿瘤的 R 值为 0.300,初始肿瘤为 0.262,首次复发为 0.360,随后复发仅为 0.533。首次复发的关键预测因子是 EGFR 和 MSH6,随后复发的关键预测因子是 HER2、EGFR 和所有 Lynch 标志物。快速复发的 R 值为 0.266,缓慢复发的 R 值为 0.370。MARS 模型均未发现 E-钙粘蛋白的相关性。总之,MARS 结果将多个 IHC 标志物与复发次数和 Ki-67 值相关联。重要的是,在初始肿瘤和首次复发之间,以及在快速复发和缓慢复发之间,发现了预测标志物的差异,这表明在总复发次数和 Ki-67 值方面,肿瘤生物学在这些亚组之间存在差异。